First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion ...Middle East

MELBOURNE, Australia, June 18, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II study of the Company's carbonic anhydrase- (CAIX)-targeting PET/CT[1] imaging agent TLX250-CDx...

Hence then, the article about first patient dosed in phase ii starburst study of tlx250 cdx exploring indication expansion was published today ( Monday 19/06/2023 - 03:13 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion )

Also on site :

• Meet the ex-Google CMO who quit with a seven-figure package by 28—he says getting promoted was easy because he just ‘disregarded all the rules’
• Marco Bezzecchi wins USA MotoGP to extend perfect start to season
• Sivers Semiconductors Announces Availability of Daybreak™ 5G/6G Advanced ICs For Emerging FR3 Applications